Topical Antibacterial Agents


Potassium Permanganate Gentian Violet Cutaneous Ulcer Iodine Compound Silver Sulfadiazine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Damour O, Hua SZ, Lasne F, et al: Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. Burns 1992; 18:479–485CrossRefPubMedGoogle Scholar
  2. 2.
    Gasset AR, Ishii Y: Cytotoxicity of chlorhexidine. Can J Ophthalmol 1975; 10:98–100PubMedGoogle Scholar
  3. 3.
    Faddis D, Daniel D, Boyer J: Tissue toxicity of antiseptic solutions. A study of rabbit articular and periarticular tissues. J Trauma 1977; 17:895–897PubMedGoogle Scholar
  4. 4.
    Kimbrough RD: Review of the toxicity of hexachlorophene. Arch Environ Health 1971; 23:119–122PubMedGoogle Scholar
  5. 5.
    Eaglstein WH, Falanga V: Chronic wounds. Surg Clin North Am 1997; 77:689–700PubMedGoogle Scholar
  6. 6.
    Murray PR, Rosenthal KS, Kobayashi GS, et al: Sterilization, disinfection, and antisepsis. In: Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA (eds) Medical Microbiology, 3rd edn. St. Louis: Mosby. 1988; pp 74–78Google Scholar
  7. 7.
    Disinfectants and preservatives. In: Kathleen Parfitt (ed) Martindale — The Complete Drug Reference, 32nd edn. London: Pharmaceutical Press. 1999; pp 1116–1117Google Scholar
  8. 8.
    Lineaweaver W, McMorris S, Soucy D, et al: Cellular and bacterial Toxicities of topical antimicrobials. Plast Reconstr Surg 1985; 75:394–396PubMedGoogle Scholar
  9. 9.
    O'Toole EA, Goel M, Woodley DT: Hydrogen peroxide inhibits human keratinocyte migration. Dermatol Surg 1996; 22:525–529CrossRefPubMedGoogle Scholar
  10. 10.
    Tur E, Bolton L, Constantine BE: Topical hydrogen peroxide treatment of ischemic ulcers in the guinea pig: blood recruitment in multiple skin sites. J Am Acad Dermatol 1995; 33:217–221CrossRefPubMedGoogle Scholar
  11. 11.
    Christensen OB, Anehus S: Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Derm Venereol (Stockh) 1994; 74:460–462Google Scholar
  12. 12.
    Disinfectants and preservatives. In: Kathleen Parfitt (ed) Martindale — The Complete Drug Reference, 32nd edn. London: Pharmaceutical Press. 1999; pg 1123Google Scholar
  13. 13.
    Southwood T, Lamb CM, Freeman J: Ingestion of potassium permanganate crystals by a three-year-old boy. Med J Aust 1987; 146:639–640PubMedGoogle Scholar
  14. 14.
    Middleton SJ, Jacyna M, McClaren D, et al: Haemorrhagic pancreatitis — a cause of death in severe potassium permanganate poisoning. Postgrad Med J 1990; 66:657–658PubMedGoogle Scholar
  15. 15.
    Rutala WA: Antisepsis, disinfection, and sterilization in hospitals and related institutions. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of Clinic Microbiology, 6th edn. Washington: ASM Press. 1995; pp 227–245Google Scholar
  16. 16.
    Disinfectants and preservatives. In: Kathleen Parfitt (ed): Martindale — The Complete Drug Reference, 32nd edn. London: Pharmaceutical Press. 1999; pp 1123–1124Google Scholar
  17. 17.
    Georgiade NG, Harris WA: Open and closed treatment of burns with povidone iodine. Plast Reconstr Surg 1973; 52:640–644PubMedGoogle Scholar
  18. 18.
    Burks RI: Povidone-iodine solution in wound treatment. Phys Ther 1998; 78:212–218PubMedGoogle Scholar
  19. 19.
    Smoot EC 3rd, Kucan JO, Roth A, et al: In vitro toxicity testing for antibacterials against human keratinocytes. Plast Reconstr Surg 1991; 87:917–924PubMedGoogle Scholar
  20. 20.
    Cooper ML, Laxer JA, Hansbrough JF: The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J Trauma 1991; 31:775–784PubMedGoogle Scholar
  21. 21.
    Kozuka T: Patch testing to exclude allergic contact dermatitis caused by povidone-iodine. Dermatology 2002; 204:96–98CrossRefPubMedGoogle Scholar
  22. 22.
    Nishioka K, Seguchi T, Yasuno H, et al: The results of ingredient patch testing in contact dermatitis elicited by povidone-iodine preparations. Contact Dermatitis 2000; 42:90–94CrossRefPubMedGoogle Scholar
  23. 23.
    Erdmann S, Hertl M, Merk HF: Allergic contact dermatitis from povidone-iodine. Contact Dermatitis 1999; 40:331–332Google Scholar
  24. 24.
    Niedner R: Cytotoxicity and sensitization of povidone-iodine and other frequently used unti-infective agents. Dermatology 1997; 195:89–92Google Scholar
  25. 25.
    Lopez Saez MP, de Barrio M, Zubeldia JM, et al: Acute lgE-mediated generalized urticaria-angioedema after application of povidone-iodine. Allergol Immunopathol (Madr) 1998; 26 23–26Google Scholar
  26. 26.
    Waran KD, Munsick RA: Anaphylaxis from povidone-iodine. Lancet 1995; 345:1506CrossRefGoogle Scholar
  27. 27.
    Pierard-Franchimont C, Paquet P, Arrese JE, et al: Healing rate and bacterial necrotizing vasculitis in venous leg ulcers. Dermatology 1997; 194:383–387PubMedGoogle Scholar
  28. 28.
    Fumal I, Braham C, Paquet P, et al: The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof of concept study. Dermatology 2002; 204:70–74CrossRefPubMedGoogle Scholar
  29. 29.
    O'Meara SM, Cullum NA, Majid M, Sheldon TA: Systemic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88:4–21CrossRefPubMedGoogle Scholar
  30. 30.
    Donohue K, Rausch H, Falanga V: Wound bed preparation. In: Rovee DT, Maibach HI (eds) The Epidermis in Wound Healing. Boca Raton, CRC Press. 2004; pp 255–264.Google Scholar
  31. 31.
    Kirsner RS, Martin LK, Drosou A: Wound microbiology and the use of antibacterial agents. In: Rovee DT, Maibach HI (eds) The Epidermis in Wound Healing. Boca Raton: CRC Press. 2004; pp 155–182.Google Scholar
  32. 32.
    Dychdala GR: Chlorine and chlorine compounds. In: Block SS (ed) Disinfection, Sterilization and Preservation. 4th edn. Philadelphia: Lea & Febiger. 1991; pp 131–151Google Scholar
  33. 33.
    Leaper DJ: Eusol: Still awaiting proper clinical trials. Br Med J 1992; 304:930–931Google Scholar
  34. 34.
    Mertz PM, Alvarez OM, Smerbeck RV, et al: A new in vivo model for the evaluation of topical antiseptics on superficial wounds. Arch Dermatol 1984; 120:58–62CrossRefPubMedGoogle Scholar
  35. 35.
    Brennan SS, Foster ME, Leaper DJ: Antiseptic toxicity in wound healing by secondary intention. J Hosp Infect 1986; 8:263–267CrossRefPubMedGoogle Scholar
  36. 36.
    Brennan SS, Leaper DJ: The effect of antiseptics on the healing wound: a study using the rabbit ear chamber. Br J Surg 1985; 72:780–782PubMedGoogle Scholar
  37. 37.
    Spadaro JA, Chase SE, Webster DA: Bacterial inhibition by electrical activation of percutaneous silver implants. J Biomed Mater Res 1986; 20:565–577CrossRefPubMedGoogle Scholar
  38. 38.
    Lansdown AB: Silver I. Its antibacterial properties and mechanism of action. J Wound Care 2002; 11:125–130PubMedGoogle Scholar
  39. 39.
    Deitch EA, Marino AA, Gillespie TE, et al: Silver-nylon: a new antimicrobial agent. Antimicrob Agents Chemother 1983; 23:356–359PubMedGoogle Scholar
  40. 40.
    Colmano G, Edwards SS, Barranco SD: Activation of antibacterial silver coatings on surgical implants by direct current: preliminary studies in rabbits. Am J Vet Res 1980; 41:964–966PubMedGoogle Scholar
  41. 41.
    Tsai WC, Chu CC, Chiu SS, et al: In vitro quantitative study of newly made antibacterial braided nylon sutures. Surg Gynecol Obstet 1987; 165:207–211PubMedGoogle Scholar
  42. 42.
    Chu CC, Tsai WC, Yao JY, et al: Newly made antibacterial braided nylon sutures. I. In vitro qualitative and in vivo preliminary biocompatibility study. J Biomed Mater Res 1987; 21:1281–1300CrossRefPubMedGoogle Scholar
  43. 43.
    Wysor MS, Zollinhofer RE: On the mode of action of silver sulphadiazine. Pathol Microbiol 1972; 38:296–308Google Scholar
  44. 44.
    Modak SM, Fox CL Jr: Binding of silver sulfadiazine to the cellular components of Pseudomonas aeruginosa. Biochem Pharmacol 1973; 22:2391–2404CrossRefPubMedGoogle Scholar
  45. 45.
    Lowbury EJ, Babb JR, Bridges K, et al: Topical chemoprophylaxis with silver sulphadiazine and silver nitrate chlorhexidine creams: emergence of sulphonamide-resistant. Gram-negative bacilli. Br Med J 1976; 1:493–496PubMedGoogle Scholar
  46. 46.
    Fuller FW, Parrish M, Nance FC: A review of the dosimetry of 1% silver sulphadiazine cream in burn wound treatment. J Burn Care Rehabil 1994; 15:213–223PubMedGoogle Scholar
  47. 47.
    Wlodkowski TJ, Rosenkranz HS: Antifungal activity of silver sulphadiazine. Lancet 1973; 2:739–740CrossRefGoogle Scholar
  48. 48.
    Wright JB, Lam K, Hansen D, et al: Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999; 27:344–350PubMedGoogle Scholar
  49. 49.
    Hidalgo E, Dominguez C: Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroplasts. Toxicol Lett 1998; 98:169–179CrossRefPubMedGoogle Scholar
  50. 50.
    Hidalgo E, Bartolome R, Barroso C, et al: Silver nitrate: antimicrobial activity related to cytotoxicity in cultured human fibroblasts. Skin Pharmacol Appl Skin Physiol 1998; 11:140–151CrossRefPubMedGoogle Scholar
  51. 51.
    McCauley RL, Li YY, Poole B, et al: Differential inhibition of human basal keratinocyte growth to silver sulfadiazine and mafenide acetate. J Surg Res 1992; 52:276–285CrossRefPubMedGoogle Scholar
  52. 52.
    Antibacterials. In: Kathleen Parfitt (ed) Martindale — The Complete Drug Reference. 32nd edn. London: Pharmaceutical Press. 1999; pp 247, 248Google Scholar
  53. 53.
    Monafo WW, Freedman B: Topical therapy for burns. Surg Clin North Am 1987; 67:133–145PubMedGoogle Scholar
  54. 54.
    Pirnay JP, De Vos D, Cochez C, et al: Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 2003; 41:1192–1202CrossRefPubMedGoogle Scholar
  55. 55.
    Yoshida T, Ohura T, Sugihara T, et al: Clinical efficacy of silver sulfadiazine (AgSD: Geben cream) for ulcerative skin lesions infected with MRSA. Jpn J Antibiot 1997; 50:39–44PubMedGoogle Scholar
  56. 56.
    Marone P, Monzillo V, Perversi L, et al: Comparative in vitro activity of silver sulfadiazine, alone and in combination with cerium nitrate, against staphylococci and gram-negative bacteria. J Chemother 1998; 10:17–21PubMedGoogle Scholar
  57. 57.
    Degreef H, Dooms-Goossens A: Patch testing with silver sulfadiazine cream. Contact dermatitis 1985; 12:33–37PubMedGoogle Scholar
  58. 58.
    McKenna SR, Latenser BA, Jones LM, et al: Serious silver sulphadiazine and mafenide acetate dermatitis. Burns 1995; 21:310–312CrossRefPubMedGoogle Scholar
  59. 59.
    Fuller FW, Engler PE: Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: a survey. J Burn Care Rehabil 1988; 9:606–609PubMedGoogle Scholar
  60. 60.
    Thomson PD, Moore NP, Rice TL, et al: Leukopenia in acute thermal injury: evidence against topical silver sulfadiazine as the causative agent. J Burn Care Rehabil 1989; 10:418–420PubMedGoogle Scholar
  61. 61.
    Chou TD, Gibran NS, Urdahl K, et al: Methemoglobinemia secondary to topical silver nitrate therapy — a case report. Burns 1999; 25:549–552CrossRefPubMedGoogle Scholar
  62. 62.
    Geronemus RG, Mertz PM, Eaglstein WH: Wound healing. The effects of topical antimicrobial agents. Arch Dermatol 1979; 115:1311–1314CrossRefPubMedGoogle Scholar
  63. 63.
    Glesinger R, Cohen AD, Bogdanov-Berezovsky A, et al: A randomized controlled trial of silver sulfadiazine, biafine, and saline-soaked gauze in the treatment of superficial partial-thickness burn wounds in pigs. Acad Emerg Med 2004; 11:339–342CrossRefPubMedGoogle Scholar
  64. 64.
    Watcher MA, Wheeland RG: The role of topical agents in the healing of full thickness wounds. J Dermatol Surg Oncol 1989; 15:1188–1195PubMedGoogle Scholar
  65. 65.
    Phillips TJ, Dover JS: Leg ulcers. J Am Acad Dermatol 1991; 25:965–987PubMedGoogle Scholar
  66. 66.
    Blair SD, Backhouse CM, Wright DDI, et al: Do dressings influence the healing of chronic venous ulcers? Phlebology 1988; 3:129–134Google Scholar
  67. 67.
    Bishop JB, Phillips LG, Mustoe TA, et al: A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg 1992; 16:251–257CrossRefPubMedGoogle Scholar
  68. 68.
    Van Den Hoogenband HM: Treatment of leg ulcers with split-thickness skin grafts. J Dermatol Surg Oncol 1984; 10:605–608PubMedGoogle Scholar
  69. 69.
    Niedner R, Schopf E: Wound infections and antibacterial therapy. In: Westerhof W (ed) Leg Ulcers: Diagnosis and Treatment. Amsterdam: Elsevier. 1993; pp 293–303Google Scholar
  70. 70.
    Saji M, Taguchi S, Uchiyama K, et al: Efficacy of gentian violet in the eradication of methicillin-resistant Staphylococcus aureus from skin lesions. J Hosp Infect 1995; 31:225–228CrossRefPubMedGoogle Scholar
  71. 71.
    Niedner R, Schopf E: Inhibition of wound healing by antiseptics. Br J Dermatol 1986; 115[Suppl]:41–44PubMedGoogle Scholar
  72. 72.
    Mobacken H: Gentian violet and wound repair. J Am Acad Dermatol 1986; 15:1303Google Scholar
  73. 73.
    Bjornberg A, Mobacken H: Necrotic skin reactions caused by 1% gentian violet and brilliant green. Acta Derm Vevereol 1972; 52:55–60Google Scholar
  74. 74.
    Mobacken H, Zederfeldt B: Influence of a cationic triphenylmethane dye on granulation tissue growth in vivo. An experimental study in rats. Acta Derm Venereol 1973; 53:167–172PubMedGoogle Scholar
  75. 75.
    Balabanova M, Popova L, Tchipeva R: Dyes in dermatology. Clin Dermatol 2003; 21:2–6CrossRefPubMedGoogle Scholar
  76. 76.
    Disinfectants and preservatives. In: Kathleen Parfitt (ed) Martindale — The Complete Drug Reference, 32nd edn. London: Pharmaceutical Press. 1999; pp 1111–1112Google Scholar
  77. 77.
    Goldwyn RM: Carl August Burow. Plast Reconstr Surg 1984; 73:687–690PubMedGoogle Scholar
  78. 78.
    Wilkinson JD: Formulary of topical applications. In: Champion RH, Burton JL, Ebling FJC (eds) Rook/Wilkinson/Ebling Textbook of Dermatology. 5th edn. Oxford: Blackwell Scientific Publications. 1992; pp 3122Google Scholar
  79. 79.
    Supplementary drugs and other substances. In: Kathleen Parfitt (ed) Martindale — The Complete Drug Reference, 32nd edn. London: Pharmaceutical Press. 1999; pp 1547Google Scholar
  80. 80.
    Thorp MA, Kruger J, Oliver S, et al: The antibacterial activity of acetic acid and Burow's solution as topical otologic preparations. J Laryngol Otol 1998; 112:925–928PubMedGoogle Scholar
  81. 81.
    Stern JC, Shah MK, Lucente FE: In vitro effectiveness of 13 agants in otomycosis and review of the literature. Laryngoscope 1988; 98:1173–1177PubMedGoogle Scholar
  82. 82.
    Clayton MI, Osborne JE, Rutherford D, et al: A double-blind, randomized, prospective trial of a topical antiseptic versus a topical antibiotic in the treatment of otorrhoea. Clin Otolaryngol 1990; 15:7–10PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations